Avid Bioservices Inc (CDMO)
17.47
-0.06
(-0.34%)
USD |
NASDAQ |
Mar 24, 16:00
17.48
+0.01
(+0.06%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.093B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -20.30% |
| Valuation | |
| PE Ratio | 10.52 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 8.693 |
| Price to Book Value | 5.894 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.7571 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 84.30% |
News
Headline
Wire
Time (ET)
SA Breaking News
03/14 10:08
MT Newswires
03/14 07:55
Yahoo
03/14 07:22
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 06/29/2023* | -- | Results | Q4 2023 | -- | 0.02 | -- | |
| 06/29/2023* | 16:30 EST | Earnings Call | Q4 2023 | -- | -- | -- | |
| 03/13/2023 | -- | Results | Q3 2023 | 0.07 | -0.04 | 283.1% | |
| 03/13/2023 | 16:30 EST | Earnings Call | Q3 2023 | -- | -- | -- | |
| 12/06/2022 | -- | Results | Q2 2023 | 0.00 | 0.02 | -124.0% | |
| 12/06/2022 | 16:30 EST | Earnings Call | Q2 2023 | -- | -- | -- | |
| 09/06/2022 | -- | Results | Q1 2023 | 0.05 | 0.04 | 46.49% | |
| 09/06/2022 | 16:30 EST | Earnings Call | Q1 2023 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development and high-quality CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. |
| URL | https://www.avidbio.com |
| Investor Relations URL | https://ir.avidbio.com |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Jun. 29, 2023 (est.) |
| Last Earnings Release | Mar. 13, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 24, 2023.
Fundamentals
| Revenue (TTM) | 140.69M |
| Total Expenses (TTM) | 136.86M |
| Net Income (TTM) | 116.47M |
| Total Assets (Quarterly) | 450.43M |
| Total Liabilities (Quarterly) | 265.04M |
| Shareholders Equity (Quarterly) | 185.40M |
| Cash from Operations (TTM) | -15.07M |
| Cash from Investing (TTM) | -77.33M |
| Cash from Financing (TTM) | 2.36M |
Ratings
Profile
Edit
| Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development and high-quality CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. |
| URL | https://www.avidbio.com |
| Investor Relations URL | https://ir.avidbio.com |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Jun. 29, 2023 (est.) |
| Last Earnings Release | Mar. 13, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| CDMO Tweets |